Combination of Anlotinib and Temozolomide Results in Sustained Response in Multimodal-Resistant Primary Breast Angiosarcoma with Metastasis to Skull Base and Dural Involvement: A Case Study - Top-Institutions - MDSpire

Combination of Anlotinib and Temozolomide Results in Sustained Response in Multimodal-Resistant Primary Breast Angiosarcoma with Metastasis to Skull Base and Dural Involvement: A Case Study

  • By

  • Shujie Song

  • Weiyi Chen

  • Xixi Li

  • Yongxia Zhang

  • Yanchun Wang

  • April 27, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Sarcoma Oncology
    • Neuro-Oncology
    • Targeted Therapy

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Sarcoma Oncology
    • Neuro-Oncology
    • Clinical Trials

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Sarcoma Research
    • Translational Medicine

  • #4

    University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical Center

    Dallas, TX

    Key Differentiators

    • Sarcoma Oncology
    • Neuro-Oncology
    • Pharmacology

Original Source(s)

Combination of Anlotinib and Temozolomide Results in Sustained Response in Multimodal-Resistant Primary Breast Angiosarcoma with Metastasis to Skull Base and Dural Involvement: A Case Study

  • by Shujie Song, Weiyi Chen, Xixi Li, Yongxia Zhang, Yanchun Wang

  • April 27, 2026

Related Content

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

Synthetic short RNA in cancer